Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) are vulnerable to coronavirus disease 2019 (COVID-19) and are at risk of inferior response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, especially if treated with the first-generation Bruton’s tyrosine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersson, Maria, Wu, Jinghua, Wullimann, David, Gao, Yu, Aberg, Mikael, Muschiol, Sandra, Healy, Katie, Naud, Sabrina, Bogdanovic, Gordana, Palma, Marzia, Mellstedt, Hakan, Chen, Puran, Ljunggren, Hans-Gustaf, Hansson, Lotta, Sallberg Chen, Margaret, Buggert, Marcus, Ingelman-Sundberg, Hanna M., Osterborg, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482612/
https://www.ncbi.nlm.nih.gov/pubmed/37692865
http://dx.doi.org/10.14740/jh1140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482612/
https://www.ncbi.nlm.nih.gov/pubmed/37692865
http://dx.doi.org/10.14740/jh1140

Ejemplares similares